logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code – Montreal
  • LINKS
  • CONTACT US
logo-top-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code – Montreal
  • LINKS
  • CONTACT US

Health Canada Guidance Document on the Disclosure of Confidential Business Information – March 10, 2017

March 10, 2017
-
Market Access News
-
Posted by MORSE Team - < 1 min read.

Health Canada Update

 

On March 10, 2017, Health Canada issued a guidance document which describes how it discloses confidential business information (CBI). This guidance document is meant for:

  • health researchers,
  • health professionals,
  • patient groups,
  • pharmaceutical industries, and
  • medical device industries.

The federal Minister of Health is authorized to disclose CBI to people to protect or promote public health or safety. As noted on the Health Canada website:

“This guidance document does not apply to other authorities in the Food and Drugs Act, which permit us to disclose CBI:

  • to a government
  • to an advisor to the Minister
  • when the Minister believes a product may pose a serious risk of injury to human health or safety

Health Canada published a draft version of this guidance document on March 10, 2016 for public consultation. The draft version was discussed in meetings with industry representatives on April 27, 2016. It was discussed with researchers, health professionals and patient groups on April 28, 2016. Written comments received from the public by May 24, 2016 were considered in revising this guidance document.”

For more information you can access the guidance document on Health Canada’s website

 

To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Confidential Business Information
Health Canada
← PREVIOUS POST
pCPA Update as of February 28, 2017
NEXT POST →
The pan-Canadian Cancer Drug Funding Sustainability Initiative

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

A one-day interactive training and networking experience in Montreal!
Cracking the Code - Strategic Canadian Public Payer Negotiations for Drug Access
NEW Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
Social
Connect & Follow:
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Health Canada Guidance Document on the Disclosure of Confidential Business Information – March 10, 2017
Learn More
Learn More